Pro Speaker

Date 01 October 2012
Event ESMO Congress 2012
Session EGFR inhibitors are the best choice for the first line treatment of EGFR mutated lung adenocarcinoma patients
Topics Anticancer agents
Non-small-cell lung cancer
Biological therapy
Presenter Tony Mok
Authors T.S.K. Mok
  • Dept. Of Clinical Oncology, Chinese University of Hong Kong Prince of Wales Hospital, - - Hong Kong/CN